Clostridium Diagnostics Market Analysis

Technology (Immunoassays-Based Clostridium Diagnostics, Molecular Clostridium Diagnostics)

The immunoassays-based clostridium segment in the clostridium diagnostics market is projected to hold 60% of the revenue share during the forecast period. The major factor to influence the growth of the market is the rising use of antibiotics. A third (33%) of respondents to a WHO/Europe poll that was performed uniformly across the 14 countries reported using antibiotics without a prescription. Furthermore, antimicrobial resistance (AMR) constitutes one of the top ten global health problems, according to the WHO, and it is thought that bacterial AMR causes 5 million deaths globally each year. The concerning truth is that by 2050, AMR might cause up to 10 million deaths annually if nothing is done. This is why the demand for immunoassays-based clostridium segment is growing. Further, they offer good specificity, are convenient to use, and produce results quickly and affordably. It has grown more challenging to assess whether a patient needs therapy since a growing percentage of individuals with positive molecular testing for CDI do not appear to have the toxins that have traditionally defined the illness. Better outcomes and accurate diagnostics are driving demand for immunoassays, which will fuel market expansion over the projected timeframe.

End User (Hospitals, Government Diagnostics Laboratories, Independent Laboratories)

Clostridium diagnostics market from the hospitals segment is set to rise by gathering the highest revenue of about 50% over the forecast period. Hospitals have experienced this growth as a result of employing better diagnostic technology over time. The majority of hospitals have testing facilities on-site or in affiliation with another facility. The use of cutting-edge methods including immunoassay and molecular diagnostic technologies in hospitals has made it feasible to diagnose Clostridium in these clinical laboratories, which is further fostering the growth of this clostridium diagnostics market. Antibiotics such as vancomycin, carbapenems, benzylpenicillin, sulfonamides, tetracyclines, metronidazole, and metronidazole are also easily available in hospitals, which contributes to the segment's growth.

Our in-depth analysis of the global clostridium diagnostics market includes the following segments: